抗リウマチ薬のヨーロッパ市場2020-2114

◆英語タイトル:EUROPE ANTI-RHEUMATICS MARKET FORECAST 2020-2028
◆商品コード:INK20MY165
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:115
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ヨーロッパ
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe Europe anti-rheumatics market is predicted to reach a CAGR of 2.10% over the forecast period of 2020-2028. A huge patient base of rheumatoid arthritis, owing to a large geriatric population, is one of the crucial factors favoring the market growth in the region.

MARKET INSIGHTS
The Europe anti-rheumatics market is researched further by segmenting the region into countries such as France, Russia, the UK, Poland, Germany, Belgium, Italy, and the rest of Europe that comprises of Greece, Austria, Netherland, Switzerland, Spain, Ireland, among others. In Russia, the prevalence of RA is estimated at 0.61% and has remained stable over the years. RA has been associated with many humanistic outcomes in spite of its low prevalence. Rheumatic disease is the second most common pathology after cardiovascular disorders, with 10% of the population being affected by RD. The most common RDs are osteoarthritis, rheumatoid arthritis, gout, and low back pain. The major factors responsible for the rising prevalence of RDs are hypertension, obesity, diabetes mellitus, and others. In countries like Belgium, the RA deaths accounted for 0.07% of the total deaths. Currently, around 80,000 to 100,000 people have this medical condition in Belgium. Since there is no known cure for RA, physicians focus on suppressing the disease. Therapies have improved in recent years, and intensive treatment in the early stages of RA can prevent joint damage and improve quality of life. The rapid improvement in therapy is driving the market.
In Poland, the most widely used DMARDs is methotrexate, which, in accordance with EULAR recommendations, is administered in RA treatment. Moreover, the program for the treatment of GPA and MPA was introduced, thereby promoting the market growth. The prevalence of RA, together with the increasing healthcare facilities, are propelling the market growth in the rest of Europe.

COMPETITIVE INSIGHTS
F. Hoffmann-La Roche Ltd, Abbott Laboratories, Novartis International AG, UCB, Becton, Dickinson, and Company, etc. are some of the renowned companies functioning in the market.

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. RISING GERIATRIC POPULATION
3.2.2. SURGE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS DISEASE
3.2.3. GROWING HEALTHCARE EXPENDITURE
3.3. KEY RESTRAINTS
3.3.1. PATENT EXPIRATIONS
3.3.2. LACK OF REGULATORY GUIDELINES FOR BIOSIMILARS WILL DELAY THEIR AVAILABILITY IN SOME REGIONS
3.3.3. LESS EXPENSIVE ALTERNATIVES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. ETIOLOGY OF RHEUMATOID ARTHRITIS (RA)
4.3. SYMPTOMS OF RHEUMATOID ARTHRITIS
4.4. RISK FACTORS ASSOCIATED WITH RHEUMATOID ARTHRITIS
4.5. OPPORTUNITY MATRIX
4.6. VENDOR LANDSCAPE
4.7. KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1. PRESCRIPTION-BASED DRUGS
5.2. OVER-THE-COUNTER DRUGS
6. MARKET BY DRUG CLASS
6.1. DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
6.2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
6.3. CORTICOSTEROIDS
6.4. URIC ACID DRUGS
6.5. OTHER DRUG CLASS
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. THE UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. ITALY
7.1.5. RUSSIA
7.1.6. BELGIUM
7.1.7. POLAND
7.1.8. REST OF EUROPE
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ABBVIE INC
8.3. AMGEN INC
8.4. BECTON, DICKINSON & COMPANY (BD)
8.5. BIO-RAD LABORATORIES INC
8.6. BRISTOL-MYERS SQUIBB COMPANY
8.7. ELI LILLY & COMPANY
8.8. LUPIN LIMITED
8.9. F. HOFFMANN-LA ROCHE
8.10. JOHNSON & JOHNSON
8.11. MERCK & CO INC
8.12. NOVARTIS AG
8.13. PERKINELMER
8.14. PFIZER INC
8.15. UCB



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[抗リウマチ薬のヨーロッパ市場2020-2114]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆